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Abstract
The canonical microRNA (miRNA) pathway commences with the enzymatic cleavage of the primary gene transcript (pri-
miRNA) by the RNAase III enzyme Drosha in the nucleus into shorter pre-miRNA species that are subsequently exported to
the cytoplasm for further processing into shorter, mature miRNA molecules. Using a series of reporter constructs, we have
previously demonstrated that phosphorylation of Drosha at Ser 300 and 302 was required for its nuclear localization. Here,
we identify GSK3b as the culprit kinase. We demonstrate that Drosha is unable to selectively localize to the nucleus in cells
deficient in GSK3b. These findings expand the substrate base of GSK3b to include a central component of the miRNA
biogenesis pathway.
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Introduction
MicroRNAs (miRNAs) are a class of endogenous nonpro-
tein-coding small RNAs of ,22 nucleotides in length that
impact gene expression by sequence specific interaction with
homologous mRNA leading to direct degradation or transla-
tional inhibition [1]–[3]. One specific miRNA may inhibit
many target genes and one specific gene may be regulated by
more than one miRNA. For example, both miRNA-125 a and
b, the genes of which are located on different chromosomes,
target the p53 protein as both miRNAs harbor similar seed
sequences that share similarity to the p53 39UTR [4],[5].
MiRNAs play increasingly recognized roles in several basic
processes including cell signal transduction, tumorigenesis,
tumor invasion and metastasis, stem cell renewal, immune
function, apoptosis and reaction to stress [6]–[10]. The human
genome is studded with some 1048 miRNA genes (miRbase;
Release September 2010). The vast majority of miRNA genes
are thought to be under the control of RNAP II with others
being recently identified as substrates of RNAP III [11],[12].
Irrespectively, miRNA genes are initially transcribed to yield a
primary, long transcript that undergoes successive processing
in both the nucleus and cytoplasm. Nuclear processing is
mediated by the RNase III enzyme Drosha to generate
precursor miRNAs (pre-miRNAs) of ,70 nucleotides in
length. Pre-miRNAs are subsequently transported to the
cytoplasm by export 5-Ran-GTP where they are cleaved by
t h eR N a s eI I Ie n z y m eD i c e rt og e n e r a t em a t u r em i R N A s[ 1 ] –
[3]. Investigation into the molecular mechanisms of miRNA
biogenesis at the transcriptional and translational levels has
been intensively pursued [12]–[15].
Drosha plays a central role in miRNA biogenesis and recent
work suggests that its expression level directly influences clinical
outcomes in malignant disease (e.g. ovarian cancer) thus
underlying the importance of better understanding mechanisms
that impact Drosha expression and function [16]–[19]. The
molecular anatomy of Drosha allows its dissection into two broad
functional domains: a C-terminus that harbors enzymatic activity
and an N-terminus that contains motifs for its nuclear localization
[20],[21]. In our previous work, we focused on the N-terminal
region of Drosha which was known to harbor a nuclear
localization signal [20]. Using a series of reporter constructs of
progressively shorter Drosha protein sequence, we narrowed
down the NLS to aa270–390. Mass spectrometric analysis,
mutagenesis and functional assays revealed that phosphorylation
of Drosha at Ser 300 and 302 was required for its correct nuclear
localization [22]. Here, we directly identify GSK3b as the culprit
kinase.
Methods
Cell culture and transfection
HeLa cells were grown in Eagle’s Minimum Essential Medium
supplemented with 10% fetal bovine serum, 2 mM L-glutamine
and non-essential amino acids. Cells were trypsinized and reseeded
in culture plates one day before transfection. HeLa cells were
transfected with Lipofectamine 2000 when cell confluency was
,70%. Mouse Embryonic Fibroblast (MEF) cells were cultured in
Dulbecco’s modified Eagle’s medium (Invitrogen, Carlsbad, CA,
USA) with 10% fetal bovine serum (Thermo Scientific), 2 mM L-
glutamine and non-essential amino acids (Invitrogen). Cells were
trypsinized and reseeded in culture plates 1 day before
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20391transfection. Transfection was performed with Lipofectamine
LTX and Plus reagent (Invitrogen) when cell confluency was
,60%.
Western blotting
Cell lysates (100 mg protein each) were separated by 4–12%
SDS–PAGE electrophoresis and electroblotted to nitrocellulose
membrane (Bio-Rad). Blotted membranes were probed with their
respective primary antibodies rotating at 4uC overnight. The
membranes were washed three times in TBST buffer and probed
with secondary antibody (Alexa Fluor 680 goat anti-rabbit IgG or
IRDye800-conjugated Affinity Purified Anti-Mouse IgG, respec-
tively) at room temperature for 1 h. Membranes were then washed
three times in TBST buffer and direct infrared fluorescence
detection was performed with a Licor OdysseyH Infrared Imaging
System [23].
In vitro kinase assays
GSK3b2/2 MEF cells were transfected with empty vector,
GFP-Drosha or GFP-DroshaS300A/S302A, respectively. For-
ty eight hours post-transfection, cell lysates were prepared with
IP/Lysis buffer (Pierce). Sepharose beads conjugated with
polyclonal antibody against GFP (Abcam) were incubated with
respective cell lysate at 4uCo v e r n i g h t .A f t e rt h r e ec y c l e so f
washing and centrifugation, the precipitates were used for an in
vitro kinase assay using
32P-ATP and pure enzyme GSK3b
(New England Biolabs) according to the manufacturer’s
instructions. The reaction products were resolved by 4–12%
SDS-PAGE gel and electroblotted to nitrocellulose membrane
(Bio-Rad). The blotted membrane was exposed to X-ray film
to visualize the phosphorylated Drosha. A synthesized peptide
(Abgent, San Diego, CA) harboring the SPSLERS motif with
flanking amino acids (H-RERHRHRDNRRSPSLERSYK-
KEYKR-CONH2) was also used for an in vitro kinase assay.
The reaction mixture which consisting of peptide and reagents
described above was dot blotted to a nitrocellulose membrane
directly and washed three times with TBST before exposing to
X-ray film.
Confocal fluorescent imaging
HeLa cells were transfected with a construct encoding GFP-
Drosha using Lipofectamine 2000. Six hours post-transfection,
the cells were treated for 20 hours with various kinase inhibitors
Figure 1. Effects of various kinase inhibitors on Drosha
localization. HeLa cells were transfected with GFP-Drosha. Six hours
post-transfection, the cells were treated with various kinase inhibitors as
indicated for 20 hours. Thirty minutes before performing confocal
imaging, 1 mg/ml Hoechst 33342 was added to the cells to stain the
nuclei. A. Solvent control; B. JNK inhibitor Sp600125; C. p38 MAPK
inhibitor SB 203580; D. CDK5 inhibitor roscovitine; E. MEK inhibitor
U0126; F. PKA inhibitor H-89; G. GSK3b inhibitor CHIR99021. Only
inhibition of GSK3b disrupted the nuclear localization of Drosha. Bar
indicates 10 micrometers.
doi:10.1371/journal.pone.0020391.g001
Figure 2. Expression levels of GSK3b protein in WT and KO MEF
cells. We confirmed GSK3b protein expression in wild type MEF cells
and its absence in GSK3b knockout MEF cells by western blot. b-Actin
was used as a protein loading control.
doi:10.1371/journal.pone.0020391.g002
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p38 MAPK inhibitor SB203580 (Sigma-Aldrich), CDK5
inhibitor roscovitine (Sigma-Aldrich), MEK inhibitor U0126
(Sigma-Aldrich), PKA inhibitor H-89 (BioVision) and GSK3b
inhibitor CHIR99021 (BioVision). MEF cells were transfected
with constructs expressing GFP, GFP-Drosha or mutated
Drosha, respectively. To determine whether GSK3b expression
restores Drosha nuclear localization in GSK3b
2/2 MEF cells,
the latter were transfected with GFP-Drosha or GFP-Drosha
and GSK3b expression construct (Adgene). Twenty-four hours
post-transfection, the cells were trypsinized and reseeded at 1:10
dilution. The cells were incubated for another 24 h. Hoechst
33342 (final concentration 1 mg/ml) was added to cell culture
30 min before confocal fluorescent imaging which was per-
formed with a LeicaTCS SP2 AOBS confocal laser microscope
[22].
Results
GSK3b emerges as a likely candidate
To identify the putative kinase(s) involved in phosphorylating
Drosha at Ser 300/302, we first mined Drosha sequence using
web based kinase prediction algorithms (e.g. KinasePhos 2.0:
http://kinasephos2.mbc.nctu.edu.tw; PPSP system: http://
ppsp.biocuckoo.org) and all identified GSK3b as the putative
kinase among other candidates. To test the veracity of these
bioinformatic predictions we first noted cellular localization
patterns of a Drosha-GFP reporter construct in the presence of
the various kinase inhibitors. With the exception of CHIR99021
(GSKb inhibitor), treatment with all other inhibitors did not
lead to cytoplasmic localization of Drosha. In contrast,
treatment with CHIR99021 led to cytoplasmic localization,
thus providing preliminary foundation for further investigation
(Figure 1). Our interest in GSK3b was further increased by
noting the presence of a classic GSK3b phosphorylation motif in
Drosha comprised of Ser-Pro-Ser-Leu-Glu-Arg-Ser (SPSLERS).
To validate these observations we performed our experiments
u s i n gaG S K 3 b knockout MEF cell line (Figure 2, Figure S1 and
Figure S2) (kindly provided by Dr. James R. Woodgett of
Samuel Lunenfeld Research Institute Toronto, Ontario, Can-
ada). We made use of the parental Drosha-GFP reporter
construct and two mutant constructs in which both Ser 300/302
were mutated to either a phospho-resistant or mimetic moiety.
We transfected constructs individually into WT and KO MEF
cells and noted their cellular distribution. As expected, WT-
Drosha and phospho-mimetic Drosha behaved similarly with
Figure 3. Phosphorylated Drosha localizes in the nucleus. A. GFP vector alone, showing diffuse expression pattern in both GSK3b wt and
knockout MEF cells; B. GFP-Drosha localizes in the nuclei in GSK3b wt MEF cells but shows a diffuse expression pattern in GSK3b knockout MEF cells;
C. Phosphorylation-deficient GFP-DroshaS300A/S302A diffusely expresses in both GSK3b wt and knockout MEF cells; D. Phosphorylation mimetic
GFP-Drosha S300E/S302D localizes in the nuclei in both GSK3b wt and knockout MEF cells.
doi:10.1371/journal.pone.0020391.g003
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construct revealed a diffuse pattern similar to a construct
encoding only GFP (Figure 3). These results suggested that
GSK3b was indeed involved in correctly localizing Drosha to
the nucleus.
GSK3b phosphorylates Drosha
To experimentally verify our bioinformatic prediction and cell
culture results, we first performed an in vitro kinase assay using a
synthetic Drosha peptide fragment harboring the putative GSK3b
phosphorylation site. Dot blot analysis revealed kinase activity upon
co-incubation of peptide fragment and recombinant GSK3b
(Figure4A).Previousreportshaveidentifiedautophosphphorylation
capacityofGSK3b and indeedwesawa faintreactioninthecontrol
lane employing enzyme only (Figure 4A). A challenge of working
with Drosha is the lack of availability of pure recombinant protein
ascribed to its size (,150 kD) [20]. To circumvent this problem, we
transfected GSK3b
2/2 MEF cells with our Drosha-GFP or
S300A/S302A mutant, respectively. A polyclonal antibody to
GFP was used to pull down adequate amounts of protein.
Importantly, both constructs expressed similar amounts of protein
upon cellular transfection. As seen in Figure 4B, Figure S3 and
FigureS4,onlythe WTconstructcouldbephosphorylatedinvitroby
GSK3b. To further confirm that GSK3b is required for Drosha
nuclear localization, a construct encoding HA-GSK3b (Addgene
cat.#14753) was co-transfected with GFP-Drosha. Overexpression
of GSK3b in GSK3b
2/2 MEF cells led to complete restoration of
phenotype with Drosha nuclear localization (Figure 5).
Discussion
GSK3b is an ubiquitous kinase implicated in many processes
central to cellular health [24]–[30]. Here, we show that this kinase
plays a central role in localization of a protein that is intimately
involved in the biogenesis of miRNA. It is important to note that
while our phospho-resistant constructs did not selectively localize
to the nucleus, as seen in the micrographs, a diffuse pattern was
observed in which some Drosha protein was present in the
nucleus. These results would seem to suggest that while GSK3b
mediated phosphorylation increases nuclear localization, other
mechanisms are also present, albeit less efficient, that lead to
localization. Exactly how important GSK3b phosphorylation of
Drosha is to the miRNA biogenesis pathway would depend upon
profiling mature miRNA levels in KO cells by array. It may be
that residual levels of Drosha are sufficient to process miRNA or
that certain miRNA species are far better substrates for the
enzyme and thereby not as sensitive to overall enzyme levels.
Finally, several reports have recently identified aberrant cellular
localization of Drosha with its presence in both cytoplasmic and
nuclear compartments. These aberrations appear to be present in
various malignancies including those of the cervix and esophagus
[31],[32]. It would be interesting to gauge what role, if any,
Figure 4. GSK3b phosphorylates Drosha at S300 and S302. In vitro kinase assays were performed using (A) peptide fragments of Drosha or
(B) immunoprecipitated Drosha protein. A. A synthetic Drosha peptide (H-RERHRHRDNRRSPSLERSYKKEYKR-CONH2) was incubated with purified
recombinant GSK3b enzyme for 1 hour. The reaction mixture (1 ml) was dot blotted to a nitrocellulose membrane and kinase activity was identified
by x-ray film exposure. B. Immunoprecipitated GFP-Drosha wt or S300A/S302A was also used for in vitro GSK3b kinase assay with or without
purified recombinant GSK3b enzyme. The reaction mixture was resolved by SDS-PAGE gel and transferred to a nitrocellulose membrane by
electrophoresis before exposing to an X-ray film. The top panel shows that GFP-Drosha wt, but not GFP-Drosha S300A/S302A, was phosphorylated
by GSK3b. The bottom panel shows that the expression levels of GFP-Drosha wt and S300A/S302A mutant were relatively equal in GSK3b knockout
MEF cells.
doi:10.1371/journal.pone.0020391.g004
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states.
Lastly, the unbridled success of imatininb has propelled the
search for other kinase inhibitors in the hopes of forwarding the
treatment of neoplastic disease. Indeed, many inhibitors of GSK3b
are in various stages of the pre-clinical pipeline [33],[34]. Given
the increasingly apparent central role that miRNA play in cellular
homeostasis, our findings suggest that GSK3b inhibitors should
perhaps be evaluated for their perturbations of global miRNA
levels prior to their consideration as potential clinical grade
reagents.
Supporting Information
Figure S1 Full gel of top panel of Figure 2. GSK3b
expression levels in WT and GSK3b
2/2 MEF cells.
(TIF)
Figure S2 Full gel of bottom panel of Figure 2. b-actin
expression in WT and GSK3b
2/2 MEF cells.
(TIF)
Figure S3 Full gel of top panel of Figure 4B. GSK3b
phosphorylates Drosha at Ser 300 and Ser 302.
(TIF)
Figure S4 Full gel of bottom panel of Figure 4B. GFP-
Drosha WT and mutant protein expression patterns are
equivalent.
(TIF)
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Figure 5. Overexpression of GSK3b in GSK3b
2/2 MEF cells localizes Drosha to the nucleus. A. HA-GSK3b plasmid was expressed in
GSK3b
2/2 MEF cells. #1,#4 shows protein expression by different colonies of HA-GSK3b plasmid upon cellular transfection. B. GSK3b
2/2 MEF cells
were transfected with GFP-Drosha plus empty vector or GFP-Drosha plus HA-GSK3b respectively. Confocal imaging was performed as in Figures 1
and 3 and revealed restoration of Drosha nuclear localization after add in of GSK3b.
doi:10.1371/journal.pone.0020391.g005
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